Two-dimensional speckle tracking echocardiography in evaluating radiation-induced heart damage

Tingcui Li, Hongqing Zhuang, Yuxia Wang, Jun Li, Dan Zhu, Ming Cui, Tingcui Li, Hongqing Zhuang, Yuxia Wang, Jun Li, Dan Zhu, Ming Cui

Abstract

Objective: Radiation-induced heart damage (RIHD) in malignant tumor patients with thoracic radiotherapy has been well documented. However, there is no study on the cardiac toxicity of stereotactic body radiotherapy (SBRT) based on two-dimensional speckle tracking echocardiography (2D STE).

Methods: In a prospective cohort trial, 48 patients with malignant tumor (including patients with lung cancer, pulmonary metastases and other tumor) were assigned to receive thoracic SBRT. Circulating biomarkers, electrocardiogram (ECG), echocardiography, and 2D STE were performed prior to and within two months after thoracic radiotherapy. The primary outcome of the trial was a decrease in global longitudinal strain (GLS) ≥ 10%. The secondary outcomes were major adverse cardiovascular events (MACE). Analysis were conducted using paired sample t-test, Wilcoxon signed rank test and Chi square test.

Results: The morbidity of RIHD is 44% within 2 months after SBRT in malignant tumor patients. Compared with pre-RT, a significant decrease in GLS was observed post-RT (-17.98 ​± ​3.54% vs. -16.92 ​± ​3.41%; P ​= ​0.008), without any significant change in left ventricular ejection fraction (LVEF) (68.54 ​± ​6.06 vs. 69.63 ​± ​4.45; P ​= ​0.234), left ventricular mass (LVM) (P ​= ​0.342), ECG parameters, creatine kinase (P ​= ​0.074), cardiac troponin T (P ​= ​0.829) or N-terminal pro-B-type natriuretic peptide (P ​= ​0.453) at during the post-RT period. There was no evidence that RIHD was correlated with age (P ​= ​1.000), mean heart dose (P ​= ​0.602), BED (P ​= ​0.234), EQD2/2 (P ​= ​0.615), V5 (P ​= ​0.506), V10 (P ​= ​0.578), V20 (P ​= ​0.670) and V30 (P ​= ​0.741). Subgroup analysis showed, there is still a significant decline of GLS (-18.30 ​± ​3.79% vs. -17.11 ​± ​3.58%; P ​= ​0.018) in patients without anthracycline treatment. And the decrease of GLS (-19.14 ​± ​2.42% vs. -16.85 ​± ​2.46%; P ​= ​0.004) was more significantly post-RT in anthracycline treatment group. MACE were found in one patient over a period of two months after SBRT.

Conclusions: By using strain analysis subclinical cardiac dysfunction was found to be evident early after SBRT, despite unchanged conventional indices such as LVEF, ECG parameters or circulating biomarkers. And the decrease of GLS is still existed after the effect of anthracycline was removed.

Trial registration: ClinicalTrials.gov, registration number: NCT04443400.

Keywords: Cardiotoxicity; Global longitudinal strain; Radiation-induced heart damage; Radiotherapy; SBRT.

© 2022 The Authors.

Figures

Figure 1
Figure 1
Enrollment, screening, and follow-up. Details regarding inclusion criteria and exclusion criteria, SBRT, and follow-up strategies are provided in the text. ECG, electrocardiogram; SBRT, stereotactic body radiotherapy; 2D STE, two-dimensional speckle tracking echocardiography; RT, radiotherapy.
Figure 2
Figure 2
Strains analysis and SBRT data. A: Representation of regional myocardial damage in a lung cancer patient with 4-chamber, 2-chamber, and 3-chamber longitudinal strain curves and segmental (bull's eye) model of GLS pre-RT; B: Representation of SBRT plan; C: Representation of regional myocardial damage in the same patient with 4-chamber, 2-chamber, and 3-chamber longitudinal strain curves and segmental (bull's eye) model of GLS post-RT. RT, radiotherapy; SBRT, stereotactic body radiotherapy; GLS, global longitudinal strain.

References

    1. Darby S.C., Ewertz M., McGale P., Bennet A.M., Blom-Goldman U., Brønnum D., et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368:987–998. 14.
    1. Tarantini L., Gulizia M.M., Di Lenarda A., Maurea N., Giuseppe Abrignani M., Bisceglia I., et al. ANMCO/AIOM/AICO consensus document on clinical and management pathways of cardio-oncology: executive summary. Eur Heart J Suppl. 2017;19:D370–D379.
    1. Gkantaifi A., Papadopoulos C., Spyropoulou D., Toumpourleka M., Iliadis G., Kardamakis D., et al. Breast radiotherapy and early adverse cardiac effects. The role of serum biomarkers and strain echocardiography. Anticancer Res. 2019;39:1667–1673.
    1. Bloom M.W., Hamo C.E., Cardinale D., Ky B., Nohria A., Baer L., et al. Cancer therapy-related cardiac dysfunction and heart failure: Part 1: dpisk factors, and imaging. Circ Heart Fail. 2016;9
    1. Skyttä T., Tuohinen S., Luukkaala T., Virtanen V., Raatikainen P., Kellokumpu-Lehtinen P.L. Adjuvant radiotherapy-induced cardiac changes among patients with early breast cancer: a three-year follow-up study. Acta Oncol. 2019;58:1250–1258.
    1. Virani S.A., Dent S., Brezden-Masley C., Clarke B., Davis M.K., Jassal D.S., et al. Canadian cardiovascular suidelines for evaluation and management of cardiovascular cancer therapy. Can J Cardiol. 2016;32:831–841.
    1. Lebesque J.V., Keus R.B. The simultaneous boost technique: the concept of relative normalized total dose. Radiother Oncol. 1991;22:45–55.
    1. Joiner M.C., Bentzen S.M. Fractionation: the linear quadratic approach. Basic Clin Radiobiol. 2018;8:102–119.
    1. Tembhekar A.R., Wright C.L., Daly M.E. Cardiac dose and survival after stereotactic body radiotherapy for early-stage non-small-cell lung cancer. Clin Lung Cancer. 2017;18:293–298.
    1. Stam B., Peulen H., Guckenberger M., Mantel F., Hope A., Werner-Wasik M., et al. Dose to heart substructures is associated with non-cancer death after SBRT in stage I-II NSCLC patients. Radiother Oncol. 2017;123:370–375.
    1. Trivedi S.J., Choudhary P., Lo Q., Sritharan H.P., Iyer A., Batumalai V., et al. Persistent reduction in global longitudinal strain in the longer term after radiation therapy in patients with breast cancer. Radiother Oncol. 2019;132:148–154.
    1. Yu A.F., Ho A.Y., Braunstein L.Z., Thor M.E., Lee Chuy K., Eaton A., et al. Assessment of early radiation-induced changes in left ventricular function by myocardial strain imaging after breast radiation therapy. J Am Soc Echocardiogr. 2019;32:521–528.
    1. Zamorano J.L., Lancellotti P., Rodriguez Muñoz D., Aboyans V., Asteggiano R., Galderisi M., et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC) Eur Heart J. 2016;37:2768–2801.
    1. Farhood B., Ashrafizadeh M., Khodamoradi E., Hoseini-Ghahfarokhi M., Afrashi S., Musa A.E., et al. Targeting of cellular redox metabolism for mitigation of radiation injury. Life Sci. 2020;250:117570.
    1. Wei J., Wang B., Wang H., Meng L., Zhao Q., Li X., et al. Radiation-induced normal tissue damage: oxidative stress and epigenetic mechanisms. Oxid Med Cell Longev. 2019;2019:3010342.
    1. Haubner F., Ohmann E., Pohl F., Prantl L., Strutz J., Gassner H.G. Effects of radiation on the expression of adhesion molecules and cytokines in a static model of human dermal microvascular endothelial cells. Clin Hemorheol Microcirc. 2013;54:371–379.
    1. Zhang J., He X., Bai X., Sun Y., Jiang P., Wang X., et al. Protective effect of trimetazidine in radiation-induced cardiac fibrosis in mice. J Radiat Res. 2020;61:657–665.
    1. Yarnold J., Brotons M.C. Pathogenetic mechanisms in radiation fibrosis. Radiother Oncol. 2010;97:149–161.
    1. Fountain M.D., McLellan L.A., Smith N.L., Loughery B.F., Rakowski J.T., Tse H.Y., et al. Isoflavone-mediated radioprotection involves regulation of early endothelial cell death and inflammatory signaling in Radiation-Induced lung injury. Int J Radiat Biol. 2020;96:245–256.
    1. Zhang K., He X., Zhou Y., Gao L., Qi Z., Chen J., et al. Atorvastatin Ameliorates Radiation-Induced Cardiac Fibrosis in Rats. Radiat Res. 2015;184:611–620.
    1. Livingston K., Schlaak R.A., Puckett L.L., Bergom C. The Role of Mitochondrial Dysfunction in Radiation-Induced Heart Disease: From Bench to Bedside. Front Cardiovasc Med. 2020;7(20)
    1. Wennstig A.K., Garmo H., Isacsson U., Gagliardi G., Rintelä N., Lagerqvist B., et al. The relationship between radiation doses to coronary arteries and location of coronary stenosis requiring intervention in breast cancer survivors. Radiat Oncol. 2019;14:40.
    1. Tuohinen S.S., Skytta T., Huhtala H., Virtanen V., Kellokumpu-Lehtinen P.L., Raatikainen P. Left ventricular speckle tracking echocardiography changes among early-stage breast cancer patients three years after radiotherapy. Anticancer Res. 2019;39:4227–4236.
    1. Chang C.C., Liou C.B., Su M.J., Lee Y.C., Liang C.T., Ho J.L., et al. Creatine kinase (CK)-MB-to-Total-CK ratio: a laboratory indicator for Primary cancer screening. Asian Pac J Cancer Prev. 2015;16:6599–6603.
    1. Wu A.H., Bowers G.N., Jr. Evaluation and comparison of immunoinhibition and immunoprecipitation methods for differentiating MB and BB from macro forms of creatine kinase isoenzymes in patients and healthy individuals. Clin Chem. 1982;28:2017–2021.
    1. Jap T.S., Wu Y.C., Ho D.M., Chiang H. Spuriously high CK-MB isoenzyme activity mimicking acute myocardial infarction in a patient with adenocarcinoma of the rectum. Zhonghua Yixue Zazhi. 2000;63:413–417.
    1. Skyttä T., Tuohinen S., Boman E., Virtanen V., Raatikainen P., Kellokumpu-Lehtinen P.L. Troponin T-release associates with cardiac radiation doses during adjuvant left-sided breast cancer radiotherapy. Radiat Oncol. 2015;10:141.
    1. Nellessen U., Zingel M., Hecker H., Bahnsen J., Borschke D. Effects of radiation therapy on myocardial cell integrity and pump function: which role for cardiac biomarkers? Chemotherapy. 2010;56:147–152.
    1. D'Errico M.P., Grimaldi L., Petruzzelli M.F., Gianicolo E.A., Tramacere F., Monetti A., et al. N-terminal pro-B-type natriuretic peptide plasma levels as a potential biomarker for cardiac damage after radiotherapy in patients with left-sided breast cancer. Int J Radiat Oncol Biol Phys. 2012;82:e239–e246.
    1. Palumbo I., Palumbo B., Fravolini M.L., Marcantonini M., Perrucci E., Latini M.E., et al. Brain natriuretic peptide as a cardiac marker of transient radiotherapy-related damage in left-sided breast cancer patients: A prospective study. Breast. 2016;25:45–50.
    1. Giordano S.H., Kuo Y.F., Freeman J.L., Buchholz T.A., Hortobagyi G.N., Goodwin J.S. Risk of cardiac death after adjuvant radiotherapy for breast cancer. J Natl Cancer Inst. 2005;97:419–424.
    1. Hooning M.J., Aleman B.M., van Rosmalen A.J., Kuenen M.A., Klijn J.G., van Leeuwen F.E. Cause-specific mortality in long-term survivors of breast cancer: a 25-year follow-up study. Int J Radiat Oncol Biol Phys. 2006;64:1081–1091.
    1. Paszat L.F., Mackillop W.J., Groome P.A., Boyd C., Schulze K., Holowaty E. Mortality from myocardial infarction after adjuvant radiotherapy for breast cancer in the surveillance, epidemiology, and end-results cancer registries. J Clin Oncol. 1998;16:2625–2631.
    1. Chang J.S., Shin J., Park E.C., Kim Y.B. Risk of cardiac disease after adjuvant radiation therapy among breast cancer survivors. Breast. 2019;43:48–54.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel